News

For the most part, these older games tend to fall in line with the “rare means valuable” rule that is common to collectibles.

StartEngine's second ICO conference attracts 1,000 attendees.

By the end of the first quarter of 2018, over $6.3 billion had already been raised through ICOs.

Netflix's richly valued stock makes its sizable debt load risky. Here's what the company should do instead.

While many tech stocks have rolled over in recent weeks, there’s one dividend-paying member of the sector that has barely budged.

Investing Strategies

StartEngine ICO 2.0 Summit Focuses on Companies' Path to Liquidity

StartEngine ICO 2.0 Summit Focuses on Companies' Path to Liquidity

StartEngine's second ICO conference attracts 1,000 attendees.

An Open Letter to Reed Hastings: Do an Equity Offering Now

An Open Letter to Reed Hastings: Do an Equity Offering Now

Netflix's richly valued stock makes its sizable debt load risky. Here's what the company should do instead.

​As Sam Sees It: With Momentum Investing Stalling, Is Now the Time to Get Defensive?

​As Sam Sees It: With Momentum Investing Stalling, Is Now the Time to Get Defensive?

A sector rotation strategy during this particular scenario facing the market has historically done quite well.

Private Markets Investing

Essential Website Planning Guide for 2018

Essential Website Planning Guide for 2018

Not sure where to start?

4 Reasons Overworking Is Overrated

4 Reasons Overworking Is Overrated

Here's why it’s important to take stock of your priorities and passions.

​Your 2004 Cellphone Headshot Doesn’t Cut It: Why You Need Professional Photography Now

​Your 2004 Cellphone Headshot Doesn’t Cut It: Why You Need Professional Photography Now

What happens when you don’t have professional portraits ready to go when needed?

Stocks

An Open Letter to Reed Hastings: Do an Equity Offering Now

An Open Letter to Reed Hastings: Do an Equity Offering Now

Netflix's richly valued stock makes its sizable debt load risky. Here's what the company should do instead.

​Why Intel Could Be a Bulletpoof Buy

​Why Intel Could Be a Bulletpoof Buy

While many tech stocks have rolled over in recent weeks, there’s one dividend-paying member of the sector that has barely budged.

Why Leaders Should Care About the Health Insurance Mandate

Why Leaders Should Care About the Health Insurance Mandate

As changes in consumer behavior in the health care marketplace unfold, insurers would be wise to rally together and develop strategic plans that will benefit their enterprises and the public.

Economy/Politics

Why Leaders Should Care About the Health Insurance Mandate

Why Leaders Should Care About the Health Insurance Mandate

As changes in consumer behavior in the health care marketplace unfold, insurers would be wise to rally together and develop strategic plans that will benefit their enterprises and the public.

Building an Empire: Magazine Publishing for Today

Building an Empire: Magazine Publishing for Today

As consumer consumption of media evolves, savvy magazine publishers must respond with innovation.

Using Personalization to Get Ahead of the Competition

Using Personalization to Get Ahead of the Competition

​For better or worse, today’s customers are spoiled. They’ve grown accustomed to personalized experiences and are drawn to companies and brands that understand them on an intimate level.

Allegiant Airlines Can Take Advantage of Its 60 Minutes of Fame or Infamy

Allegiant Airlines Can Take Advantage of Its 60 Minutes of Fame or Infamy

It depends on how it handles the crisis at hand.

Special Sections

Corvidia Therapeutics Closes $60 Million Series B Round Led by Venrock

Corvidia Therapeutics Closes $60 Million Series B Round Led by Venrock

Using precision genomics to develop cardiovascular and cardio-renal therapies.

Alnylam Presents Positive Results from Phase 3 Study of Hereditary ATTR Amyloidosis Therapy

Alnylam Presents Positive Results from Phase 3 Study of Hereditary ATTR Amyloidosis Therapy

Reduced hospitalization and mortality by 50% and demonstrated improvement in multiple quality of life measures.

Ultragenyx Gets FDA Approval for X-Linked Hypophosphatemia (XLH) Drug

Ultragenyx Gets FDA Approval for X-Linked Hypophosphatemia (XLH) Drug

First approved therapy for XLH in the US and only treatment targeting the underlying cause of this rare, hereditary, lifelong disease.​

Amgen Presents Full Positive Phase 3b Results of Migraine Drug Aimovig

Amgen Presents Full Positive Phase 3b Results of Migraine Drug Aimovig

Aimovig cut migraine days in half for 30% of trial patients who had failed up to four previous treatments (Image: PharmaTimes).

Emerging Growth

Lomiko Metals Inc.

Lomiko Metals Inc is an exploration stage company. It is engaged in the acquisition, exploration and development of resource properties. Its projects include Vines Lake project and Quatre - Milles…

Private Markets

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.

The Green Organic Dutchman

The Green Organic Dutchman Ltd. ("TGOD") produces farm grown, organic cannabis for medical use. The company grows its high quality organic cannabis in small batches using craft growing, all natural…